Agents tageting small interfering RNAs (siRNA) for use in cancer have been developed. The phase 1 clinical trials are over and the results were recently published in Nature.
CALAA-01 is a nanoparticle drug containing small interfering RNAs targeted to ribonucleside reductase M2. This is used in solid tumors that are refractory to therapy.
This opens an entirely new class of anticancer agents.
Microbiology Lecture Notes - SET 4
-
Powerpoint links collected from the website of :
Lauren Brandon, Ph.D , Associate Professor of Microbiology
Introduction to Microbiology
Microbial Cell...
7 years ago
No comments:
Post a Comment
Add your comment